Alcohol-related Liver Disease, Liver Histology, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, Metabolic Dysfunction Associated Steatotic Liver Disease, Myosteatosis, Steatotic Liver Disease of Mixed Origin (MetALD), Steatotic Liver Diseases
Conditions
Keywords
myosteatosis, steatotic liver disease, metabolic dysfunction-associated steatotic liver disease, alcohol-related liver disease, MetALD, magnetic resonance imaging, magnetic resonance spectroscopy, liver biopsy
Brief summary
Steatotic liver diseases (SLD) are the most common chronic liver diseases worldwide. SLD are defined by an excessive liver lipid content (steatosis) of more than 5% of the total liver weight and includes 3 clinical entities : metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD) and a mixed entity combining the two settings referred as MetALD. SLD are associated to extra-hepatic complications such as cardiovascular diseases, insulin resistance or muscle changes. Among the latter, myosteatosis, defined by an excessive muscle fat content, has been reported as a muscle change in MASLD occuring even in non-cirrhotic stages. Investigators will explore these muscle changes in SLD patients according to the severity of the underneath liver disease.
Detailed description
This project investigates the correlation between liver and muscle phenotypes assessed in a cohort of all 3 SLD subgroups (MASLD, ALD and MetALD). If a severe form of SLD is suspected based on a severely increased liver elasticity, assessed by transient elastography, participants undergo a liver biopsy, liver and muscle magnetic resonance imaging. Eating habits and physical activity level are recorded using the 24 hour-recall and international physical activity questionnaire. Psychological disorders are also screened using dedicated questionnaires.
Interventions
None listed
Sponsors
Fonds National de la Recherche Scientifique
Concerted Research Action
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Age between18 to 75 years * Presence of hepatic steatosis, suggested by a controlled attenuation parameter (CAP) ≥ 252 dB/m on elastometry and elevated transaminases (ALT ≥ 25 or 33 IU/L in women or men respectively) * Presence of overweight (BMI > 25 kg/m²), obesity (BMI > 30 kg/m²), metabolic syndrome, prediabetes or type 2 diabetes. Metabolic syndrome is defined by int ernational Diabetes Federation as follows : waist circumference ≥ 94/80cm for men/women with ≥ 2 other criteria: arterial pressure ≥ 130/85 mmHg or treatment for hypertension, fasting glucose ≥ 130/85 mmHg or treatment for hypertension, serum triglycerides > 150 mg/dl or treatment for dyslipidemia, HDL cholesterol < 40/50 mg/dl for men/women or treatment for dyslipidemia.
Exclusion criteria
* Liver disease from other causes (alcohol, active viral chronic hepatitis B or C, Wilson's disease, autoimmune hepatitis, alpha1-anti-trypsin deficiency,...) * Heavy consumption of alcoholic beverages, i.e. > 140 g or 210 g of ethanol in women or men respectively). * Intravenous drug use * HbA1C > 10% * Decompensated cirrhosis (presence of ascites, bilirubin level > 1.2 mg/dL in a patient without Gilbert's syndrome, albumin level < 35 g/L) * Pregnancy * Use of drugs that may cause steatosis (methotrexate, amiodarone, tamoxifen, oral corticosteroids) currently or in the last 3 months * Change in treatment of hyperglycaemia (dose or medication) in the last 3 months * Change in body weight >5% in the last 3 months * Active cancer * End stage renal disease or dialysis * Type 1 diabetes or secondary diabetes * Digestive malabsorption * Untreated thyroid disease * Taking a treatment under study or approved for NASH (semaglutide, lanifibranor, obeticholic acid). * Musculoskeletal disorders, neuromuscular or inflammatory diseases such as connective tissue diseases, myositis and vasculitis that have musculoskeletal manifestations.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| correlation between muscle mass and fat content and liver histological features of SLD | MRI and liver biopsy are performed at Day 1 | muscle mass and fat content will be assessed by magnetic resonance imaging and spectroscopy. Liver phenotype will be histologically assessed by 3 blinded pathologists and computer-assisted morphometry. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| liver molecular mechanisms involved in myosteatosis pathogenesis | liver samples are collected during the biopsy | mRNA extraction and sequencing from liver tissue samples collected during liver biopsy to assess the transcriptomic pattern correlating with muscle fat assessed by MRI. |
| impact of muscle fat content on muscle function | muscle function tests are performed 1-week after the biopsy/MRI (Day 7) | investigators assess the correlation between muscle fat assessed by MRI and muscle function assessed by several tests. |
Countries
Belgium
Outcome results
None listed